David S. Shames - Concepedia

Author

David S. Shames

The University of Texas Southwestern Medical Center ORCID

Also Known As

D S Shames, D. Shames, D.S. Shames, DAVID S. SHAMES, David S Shames, David S. Shames, David Shames, David S. Shames, Gerald, William, Lee A Albacker

311

Publications

19.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center The University of Texas MD Anderson Cancer Center Roche (Switzerland)Foundation Medicine (United States)

About

David S. Shames is an author at The University of Texas Southwestern Medical Center specializing in medicine, lung cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	47	7.8K
2	Health Sciences	3	3	239
3	Engineering	2	2	243
4	Natural Sciences	1	1	184
5	Public Health	1	1	343

David S. Shames

Publications

17.8K

Citations

H-Index

Page 1

	Year	Citations
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, New England Journal of Medicine	2018	3.3K
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab David R. Gandara, Sarah Paul, Marcin Kowanetz, Nature Medicine OncologyPathologyBronchial NeoplasmClinical BenefitCancer Genetics	2018	1.2K
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Charles M. Rudin, Steffen Durinck, Eric Stawiski, Nature Genetics MedicinePathologyCancer GenomicsBronchial NeoplasmCancer Genetics	2012	1.1K
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Cancer Cell ImmunogeneticsSystems BiologyDistinct Therapeutic VulnerabilitiesAutoimmune DiseaseTranscription Factor Programs	2021	864
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Nature Adjuvant ImmunotherapyCancer ImmunosurveillanceUrologyGenitourinary Cancer	2021	578
The mutation spectrum revealed by paired genome sequences from a lung cancer patient William Lee, Zhaoshi Jiang, Jinfeng Liu, Nature Paired Genome SequencesMutation SpectrumSomatic VariantTumor HeterogeneityMedicine	2010	500
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Tony Mok, Yi‐Long Wu, Jin Soo Lee, Clinical Cancer Research	2015	468
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer Namrata S. Patil, Barzin Y. Nabet, Sören Müller, Cancer Cell Intratumoral Plasma CellsCancer ImmunosurveillancePd-l1 BlockadeMedicineImmunology	2022	371
Quantitative comparison of DNA methylation assays for biomarker development and clinical applications Christoph Bock, Florian Halbritter, Francisco javier García Carmona, Nature Biotechnology Epigenetic ChangeGeneticsDna MethylationGenetic EpidemiologyDna Methylation Assays	2016	343
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing Bethany A. Janowski, Kenneth E. Huffman, Jacob C. Schwartz, Nature Structural & Molecular Biology Transcriptional RegulationGene RegulationGene ExpressionMedicineCell Biology	2006	324

Page 1